Safety and efficacy of 177Lu-PSMA-I&T Radioligand Therapy in Octogenarians with metastatic castration-resistant prostate cancer: Report on eighty patients over age eighty
Nuklearmedizin-nuclear Medicine(2023)
摘要
Ziel/Aim 177Lu-PSMA radioligand (RLT) therapy is a new treatment option for metastatic castration-resistant prostate cancer (mCRPC). Its low toxicity profile favors the use in elderly patients. Purpose of this study was to evaluate the safety and efficacy of 177Lu-PSMA-RLT in mCRPC patients≥80 years of age.
更多查看译文
关键词
prostate cancer,lu-psma-i,castration-resistant
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要